Swathi Lavudi, MD
Nephrology · Grand Island, NENPI 1114367547
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Fresenius USA Marketing, Inc. at 28.2% of the total. 2025 is the largest year on record at $414, 2.6 times the $161 reported in 2019.
Across 84 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$407
- Amgen$217
- AstraZeneca$123
- Travere Therapeutics, Inc.$106
- Vifor Pharma, Inc.$79
- Bayer$78
- plus $432 from 17 others
What the payments were for
- Food & beverage$1,40798%
- Education$352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 25 | $407 |
| Amgen | 10 | $217 |
| AstraZeneca | 7 | $123 |
| Travere Therapeutics, Inc. | 10 | $106 |
| Vifor Pharma, Inc. | 4 | $79 |
| Bayer | 5 | $78 |
| Mallinckrodt Hospital Products Inc. | 3 | $66 |
| Exact Sciences | 3 | $53 |
| Boehringer Ingelheim | 2 | $40 |
| Novartis | 2 | $37 |
| Calliditas Therapeutics US Inc. | 1 | $26 |
| Sanofi | 1 | $26 |
| Medtronic | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Amicus Therapeutics, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Novo Nordisk | 1 | $14 |
How this compares
$1,441 in reported general payments places this provider in the 55th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 80 | $316,149 |
| FarxigaDapagliflozin Propanediol | 206 | $147,933 |
| XphozahTenapanor Hcl | 13 | $61,709 |
| JardianceEmpagliflozin | 68 | $57,018 |
| AuryxiaFerric Citrate | 39 | $51,615 |
| Sevelamer Carbonate | 187 | $33,700 |
| DapagliflozinDapagliflozin Propanediol | 17 | $8,186 |
| Torsemide | 159 | $3,580 |
| Calcitriol | 244 | $3,063 |
| Losartan Potassium | 271 | $2,503 |
| Hydralazine Hcl | 74 | $1,549 |
| Potassium Chloride | 76 | $1,544 |
| Amlodipine Besylate | 125 | $1,093 |
| Allopurinol | 58 | $911 |
| Midodrine Hcl | 19 | $905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $407 | $316,14980 claims |
| AstraZenecaFarxiga | $123 | $147,933206 claims |
| Boehringer IngelheimJardiance | $40 | $57,01868 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 60 nephrology providers in Nebraska.
Other nephrology in Grand Island
- Timothy GovaertsGrand Island$432
- Michael AaronsonLincoln$498K
- Richard LundOmaha$378K
- Jeffrey PasserOmaha$146K
- Rachel BrockLincoln$87K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Eric MagliuloOmaha$9K
- Prasanth RavipatiOmaha$7K
- Joseph BastOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.